Crewe Advisors’s Editas Medicine EDIT Stock Holding History

Crewe Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,900	Closed	-$14.1K	–	965
2024 Q1	$14.1K	Buy	+1,900	New	+$15.8K	﹤0.01%	561

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Crewe Advisors's EDIT Position: Q2 2024 in Review

Crewe Advisors sold out of Editas Medicine (EDIT) in Q2 2024, closing a stake of 1,900 shares — an estimated $14.1K sold.

Crewe Advisors first reported a position in EDIT in Q1 2024 and held it in 1 quarter. The position peaked at $14.1K in Q1 2024. 235 funds tracked by Wall St. Rank hold EDIT as of Q2 2024.

Crewe Advisors reported no remaining Editas Medicine position as of Q2 2024 after selling out during the quarter.
Crewe Advisors sold 1,900 Editas Medicine shares in Q2 2024, an estimated $14.1K.
Crewe Advisors first reported a position in Editas Medicine in Q1 2024 and held it in 1 quarter.
Crewe Advisors's Editas Medicine position peaked at $14.1K in Q1 2024.
235 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2024.

Based on Crewe Advisors's 13F filing for Q2 2024, filed 29 Jul 2024.